1. Gentamicin in the Treatment of Meningitis in Neonates
- Author
-
John M. Leedom, Paul F. Wehrle, Allen W. Mathies, Daniel Ivler, and Warren Ws
- Subjects
medicine.medical_specialty ,Severe disease ,Sepsis ,Enterobacteriaceae ,Kanamycin ,Salmonella ,Klebsiella ,Pseudomonas ,Case fatality rate ,Escherichia coli ,medicine ,Humans ,Immunology and Allergy ,Meningitis ,Intensive care medicine ,Cerebrospinal Fluid ,Suppuration ,Acinetobacter ,business.industry ,Infant, Newborn ,Proteus ,medicine.disease ,Chloramphenicol ,Infectious Diseases ,Ampicillin ,Bacterial meningitis ,Gentamicin ,Gentamicins ,business ,medicine.drug - Abstract
Bacterial meningitis and "sepsis," confirmed by positive blood cultures when they occur during the first 30 days of life, present perhaps the greatest current challenges to the antimicrobial therapist. As detailed below for meningitis, case fatality rates are high, and the survivors frequently have crippling sequelae. This is true in spite of the fact that many of the patients have no obvious underlying severe disease and should be salvageable. Certainly, the infectious processes are not always promptly controlled by standard antimicrobials, and the over-all case fatality and residua rates leave ample scope for improvement in the results of therapy.
- Published
- 1969
- Full Text
- View/download PDF